MorphoSys AG — M&A Activity 2001

Jun 21, 2001

News Details

Ad-hoc | 21 June 2001 07:50

MorphoSys AG english

Ad hoc announcement processed and transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– MorphoSys and ImmunoGen Expand Existing Collaboration – License of HuCAL for Target Research Martinsried/Muenchen, — 21. Juni 2001 — MorphoSys AG (Neuer Markt: MOR) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a research agreement under which ImmunoGen will license MorphoSys HuCAL (Human Combinatorial Antibody Library) technology for the generation of research antibodies. This agreement extends the current therapeutic antibody collaboration, announced on October 2, 2000, under which MorphoSys is developing fully human antibodies to a single ImmunoGen target. Under this new agreement, ImmunoGen will pay MorphoSys technology access and annual subscription fees during a four-year term. end of ad hoc announcement (c) DGAP 21.06.2001 ——————————————————————————– WKN: 663200; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 210750 Jun 01